Jazz Pharma Q1 2025 Sales Dip

Ticker: JAZZ · Form: 10-Q · Filed: May 7, 2025 · CIK: 1232524

Jazz Pharmaceuticals PLC 10-Q Filing Summary
FieldDetail
CompanyJazz Pharmaceuticals PLC (JAZZ)
Form Type10-Q
Filed DateMay 7, 2025
Risk Levelmedium
Sentimentbearish

Sentiment: bearish

Topics: earnings, revenue-decline, pharmaceuticals

TL;DR

Jazz Pharma Q1 sales down to $864.9M from $922.7M YoY. Watchlist.

AI Summary

Jazz Pharmaceuticals plc filed its 10-Q for the period ending March 31, 2025. The company reported net product sales of $854.4 million for the first quarter of 2025, a decrease from $911.8 million in the same period of 2024. Royalties and contract revenue also saw a slight decline from $10.9 million in Q1 2024 to $10.5 million in Q1 2025.

Why It Matters

This filing indicates a revenue decrease for Jazz Pharmaceuticals in early 2025, which could impact investor confidence and future growth projections.

Risk Assessment

Risk Level: medium — The decrease in product sales and royalties suggests potential market challenges or product lifecycle issues that could affect future financial performance.

Key Numbers

Key Players & Entities

FAQ

What were Jazz Pharmaceuticals' net product sales for the first quarter of 2025?

Net product sales for the first quarter of 2025 were $854.4 million.

How do Q1 2025 net product sales compare to Q1 2024?

Net product sales decreased from $911.8 million in Q1 2024 to $854.4 million in Q1 2025.

What was the revenue from royalties and contract for Q1 2025?

Royalties and contract revenue for Q1 2025 amounted to $10.5 million.

Did royalties and contract revenue increase or decrease compared to Q1 2024?

Royalties and contract revenue decreased from $10.9 million in Q1 2024 to $10.5 million in Q1 2025.

What is the total revenue for Jazz Pharmaceuticals for the first quarter of 2025?

The total revenue for the first quarter of 2025, combining net product sales and royalties/contract revenue, is $864.9 million ($854.4M + $10.5M).

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 7, 2025 regarding Jazz Pharmaceuticals plc (JAZZ).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing